Imperial College London

Jiri Pavlu

Faculty of MedicineDepartment of Immunology and Inflammation

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

+44 (0)20 3313 8117j.pavlu Website

 
 
//

Location

 

Leuka Building R2.20Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Pavlu:2019:10.1186/s13045-019-0790-x,
author = {Pavlu, J and Labopin, M and Niittyvuopio, R and Socie, G and Yakoub-Agha, I and Wu, D and Remenyi, P and Passweg, J and Beelen, DW and Aljurf, M and Kroeger, N and Labussiere-Wallet, H and Peric, Z and Giebel, S and Nagler, A and Mohty, M},
doi = {10.1186/s13045-019-0790-x},
journal = {Journal of Hematology and Oncology},
pages = {1--9},
title = {Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT},
url = {http://dx.doi.org/10.1186/s13045-019-0790-x},
volume = {12},
year = {2019}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - BackgroundAssessment of measurable residual disease (MRD) is rapidly transforming the therapeutic and prognostic landscape of a wide range of hematological malignancies. Its prognostic value in acute lymphoblastic leukemia (ALL) has been established and MRD measured at the end of induction is increasingly used to guide further therapy. Although MRD detectable immediately before allogeneic hematopoietic cell transplantation (HCT) is known to be associated with poor outcomes, it is unclear if or to what extent this differs with different types of conditioning.MethodsIn this retrospective registry study, we explored whether measurable residual disease (MRD) before allogeneic hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia is associated with different outcomes in recipients of myeloablative total body irradiation (TBI)-based versus chemotherapy-based conditioning. We analyzed outcomes of 2780 patients (median age 38 years, range 18–72) who underwent first HCT in complete remission between 2000 and 2017 using sibling or unrelated donors.ResultsIn 1816 of patients, no disease was detectable, and in 964 patients, MRD was positive. Conditioning was TBI-based in 2122 (76%) transplants. In the whole cohort MRD positivity was a significant independent factor for lower overall survival (OS) and leukemia-free survival (LFS), and for higher relapse incidence (RI), with respective hazard ratios (HR, 95% confidence intervals) of 1.19 (1.02–1.39), 1.26 (1.1–1.44), and 1.51 (1.26–1.8). TBI was associated with a higher OS, LFS, and lower RI with HR of 0.75 (0.62–0.90), 0.70 (0.60–0.82), and 0.60 (0.49–0.74), respectively. No significant interaction was found between MRD status and conditioning. When investigating the impact of MRD separately in the TBI and chemotherapy-based conditioning cohorts by multivariate analysis, we found MRD positivity to be associated with lower OS and LFS and higher RI in the TBI gro
AU - Pavlu,J
AU - Labopin,M
AU - Niittyvuopio,R
AU - Socie,G
AU - Yakoub-Agha,I
AU - Wu,D
AU - Remenyi,P
AU - Passweg,J
AU - Beelen,DW
AU - Aljurf,M
AU - Kroeger,N
AU - Labussiere-Wallet,H
AU - Peric,Z
AU - Giebel,S
AU - Nagler,A
AU - Mohty,M
DO - 10.1186/s13045-019-0790-x
EP - 9
PY - 2019///
SN - 1756-8722
SP - 1
TI - Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT
T2 - Journal of Hematology and Oncology
UR - http://dx.doi.org/10.1186/s13045-019-0790-x
UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000495017700001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR - https://jhoonline.biomedcentral.com/articles/10.1186/s13045-019-0790-x
UR - http://hdl.handle.net/10044/1/75819
VL - 12
ER -